Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Schistosoma mansoni | norepinephrine/norepinephrine transporter | 0.0329 | 0.8459 | 1 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Brugia malayi | vesicular acetylcholine transporter unc-17 | 0.023 | 0.5641 | 0.5322 |
Brugia malayi | Sodium:neurotransmitter symporter family protein | 0.0329 | 0.8459 | 0.8346 |
Echinococcus granulosus | serotonin transporter | 0.0329 | 0.8459 | 1 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Echinococcus multilocularis | vesicular acetylcholine transporter | 0.023 | 0.5641 | 0.6377 |
Schistosoma mansoni | hypothetical protein | 0.0103 | 0.2021 | 0.1721 |
Loa Loa (eye worm) | hypothetical protein | 0.0383 | 1 | 1 |
Echinococcus multilocularis | solute carrier family 2, facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Loa Loa (eye worm) | vesicular acetylcholine transporter unc-17 | 0.023 | 0.5641 | 0.5322 |
Schistosoma mansoni | sodium/chloride dependent transporter | 0.0329 | 0.8459 | 1 |
Schistosoma mansoni | vesicular acetylcholine transporter | 0.023 | 0.5641 | 0.6377 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Onchocerca volvulus | Vesicular acetylcholine transporter homolog | 0.023 | 0.5641 | 0.6377 |
Trypanosoma brucei | C-8 sterol isomerase, putative | 0.0383 | 1 | 1 |
Trichomonas vaginalis | conserved hypothetical protein | 0.0103 | 0.2021 | 1 |
Echinococcus granulosus | General substrate transporter | 0.0088 | 0.1609 | 0.1192 |
Loa Loa (eye worm) | solute carrier family 6 member 4 | 0.0329 | 0.8459 | 0.8346 |
Schistosoma mansoni | glucose transport protein | 0.0103 | 0.2021 | 0.1721 |
Schistosoma mansoni | glucose transport protein | 0.0103 | 0.2021 | 0.1721 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Loa Loa (eye worm) | hypothetical protein | 0.0329 | 0.8459 | 0.8346 |
Loa Loa (eye worm) | hypothetical protein | 0.0196 | 0.4667 | 0.4277 |
Echinococcus granulosus | vesicular acetylcholine transporter | 0.023 | 0.5641 | 0.6377 |
Plasmodium falciparum | hexose transporter | 0.0103 | 0.2021 | 1 |
Schistosoma mansoni | glucose transport protein | 0.0103 | 0.2021 | 0.1721 |
Toxoplasma gondii | facilitative glucose transporter GT1 | 0.0103 | 0.2021 | 1 |
Chlamydia trachomatis | Ssodium-dependent amino acid transporter | 0.0056 | 0.0682 | 0.5 |
Echinococcus multilocularis | serotonin transporter | 0.0329 | 0.8459 | 1 |
Echinococcus granulosus | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Loa Loa (eye worm) | hypothetical protein | 0.0329 | 0.8459 | 0.8346 |
Echinococcus multilocularis | solute carrier family 2 facilitated glucose | 0.0103 | 0.2021 | 0.1721 |
Plasmodium vivax | hexose transporter | 0.0103 | 0.2021 | 1 |
Loa Loa (eye worm) | sugar transporter | 0.0103 | 0.2021 | 0.1437 |
Treponema pallidum | sodium- and chloride- dependent transporter | 0.0329 | 0.8459 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0329 | 0.8459 | 0.8346 |
Echinococcus multilocularis | General substrate transporter | 0.0088 | 0.1609 | 0.1192 |
Onchocerca volvulus | 0.0329 | 0.8459 | 1 | |
Loa Loa (eye worm) | serotonin transporter b | 0.0329 | 0.8459 | 0.8346 |
Brugia malayi | Sugar transporter family protein | 0.0103 | 0.2021 | 0.1437 |
Loa Loa (eye worm) | norepinephrine transporter | 0.0329 | 0.8459 | 0.8346 |
Trypanosoma cruzi | C-8 sterol isomerase, putative | 0.0383 | 1 | 1 |
Leishmania major | C-8 sterol isomerase-like protein | 0.0383 | 1 | 1 |
Activity type | Activity value | Assay description | Source | Reference |
---|---|---|---|---|
Decrease (functional) | 0 % | % decrease in adrenal epinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 35 mg/kg dose perorally; NA is not available | ChEMBL. | 2909730 |
Decrease (functional) | 0 % | % decrease in adrenal epinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 75 mg/kg dose perorally; NA is not available | ChEMBL. | 2909730 |
Decrease (functional) | 0 % | % decrease in adrenal epinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 150 mg/kg dose perorally; NA is not available | ChEMBL. | 2909730 |
Decrease (functional) | = 7 % | % decrease in heart 5-HT in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 35 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 12 % | % decrease in hypothalamus norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 35 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 16 % | % decrease in hypothalamus norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 75 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 26 % | % decrease in hypothalamus dopamine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 75 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 28 % | % decrease in hypothalamus norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 150 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 29 % | % decrease in hypothalamus dopamine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 35 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 29 % | % decrease in heart 5-HT in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 75 mg/kg dose perorally; *value significantly different was control. | ChEMBL. | 2909730 |
Decrease (functional) | = 37 % | % decrease in heart 5-HT in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 150 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 37 % | % decrease in hypothalamus 5-HT in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 150 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 55 % | % decrease in heart norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 35 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 61 % | % decrease in heart norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 75 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease (functional) | = 70 % | % decrease in heart norepinephrine in anesthetized spontaneously hypertensive rats(SHR) at 5 hours after administration of 150 mg/kg dose perorally | ChEMBL. | 2909730 |
Decrease in Systolic blood pressure (functional) | NA 0 % | Compound was evaluated for systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats(SHR) at 7.5 hours after administration of 75 mg/kg dose intravenously; NS is not statstically significant | ChEMBL. | 2909730 |
Systolic blood pressure (functional) | = 0 | Compound was evaluated for systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats(SHR) before administration of 35 mg/kg dose perorally | ChEMBL. | 2909730 |
Systolic blood pressure (functional) | = 4 | Systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats (SHR) before administration of 75 mg/kg dose perorally. | ChEMBL. | 2909730 |
Systolic blood pressure (functional) | = 16 | Compound was evaluated for systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats(SHR) before administration of 150 mg/kg dose perorally | ChEMBL. | 2909730 |
Systolic blood pressure (functional) | = 194 | Systolic blood pressure (SBP) in anesthetized spontaneously hypertensive rats (SHR) before administration of 75 mg/kg dose perorally. | ChEMBL. | 2909730 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
1 literature reference was collected for this gene.